RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value per share (RAPT)

Historical Holders from Q4 2019 to Q1 2025

Symbol
RAPT on Nasdaq
CUSIP
75382E109
Type / Class
Equity / Common Stock, $0.0001 par value per share
Shares outstanding
141M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
127M
Holdings value
$199M
% of all portfolios
0.002%
Grand Portfolio weight change
+0%
Number of holders
91
Number of buys
54
Number of sells
-50
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value per share (RAPT)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Medicxi IV LP 16.9% $27.3M 22.4M Medicxi IV GP Limited Dec 27, 2024
Deep Track Capital, LP 9.87% $17.2M 14.1M Deep Track Capital, LP Dec 23, 2024
Redmile Group, LLC 9.9% $17M 13.9M Redmile Group, LLC Dec 31, 2024
TCG Crossover GP II, LLC 9.99% $16.1M 13.2M TCG Crossover GP II, LLC Dec 27, 2024
ORBIMED ADVISORS LLC 9.9% $16M 13.1M ORBIMED ADVISORS LLC Dec 31, 2024
Foresite Capital Fund VI LP 9.3% $15.3M 12.5M Foresite Capital Fund VI, L.P. Dec 23, 2024
BIOTECHNOLOGY VALUE FUND L P 8.7% $14.4M 11.8M BVF PARTNERS L P/IL Dec 27, 2024
PERCEPTIVE ADVISORS LLC 4.5% $7.17M 5.88M Perceptive Advisors LLC Dec 31, 2024
VANGUARD GROUP INC 2.22% $3.58M 2.93M The Vanguard Group Jan 31, 2025
COLUMN GROUP II, LP 4.9% $1.96M 1.6M Peter Svennilson Dec 23, 2024
FMR LLC 0.4% $586K 481K FMR LLC Jan 31, 2025

Institutional Holders of RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value per share (RAPT)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 22.7M $27.7M -$32.4K $1.22 7
2024 Q4 127M $199M +$131M $1.58 91
2024 Q3 29.8M $59.9M -$5.4M $2.01 93
2024 Q2 31.8M $97M -$17.6M $3.05 104
2024 Q1 17.7M $159M -$170M $8.98 67
2023 Q4 35M $869M -$307K $24.85 108
2023 Q3 34.8M $578M +$6.72M $16.62 98
2023 Q2 34.1M $637M +$14.4M $18.70 98
2023 Q1 33.3M $611M +$19.8M $18.35 104
2022 Q4 32.1M $635M +$67.4M $19.80 92
2022 Q3 29.2M $702M -$15.8M $24.06 91
2022 Q2 28.7M $523M +$30.2M $18.25 83
2022 Q1 28M $615M -$10.2M $21.99 79
2021 Q4 27.7M $1.02B +$58.6M $36.73 99
2021 Q3 26.2M $774M -$11.9M $31.05 104
2021 Q2 26.6M $804M +$200M $31.79 107
2021 Q1 21.1M $468M +$14.6M $22.20 77
2020 Q4 19.7M $389M -$1.78M $19.75 78
2020 Q3 16.8M $542M +$65.3M $32.20 66
2020 Q2 14.8M $430M +$93.9M $29.02 52
2020 Q1 11.7M $248M +$53.9M $21.27 36
2019 Q4 9.14M $252M +$252M $27.61 26